These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10618534)

  • 41. Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme.
    Huemer HP; Strobl B; Nowotny N
    Vaccine; 2000 Jan; 18(14):1320-6. PubMed ID: 10618528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection.
    Paillot R; Ellis SA; Daly JM; Audonnet JC; Minke JM; Davis-Poynter N; Hannant D; Kydd JH
    Vaccine; 2006 Mar; 24(10):1490-500. PubMed ID: 16269205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dendritic cells presenting equine herpesvirus-1 antigens induce protective anti-viral immunity.
    Steinbach F; Borchers K; Ricciardi-Castagnoli P; Ludwig H; Stingl G; Elbe-Bürger A
    J Gen Virol; 1998 Dec; 79 ( Pt 12)():3005-14. PubMed ID: 9880015
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Equine herpesvirus type 1 mutant defective in glycoprotein E gene as candidate vaccine strain.
    TSUJIMURA K; SHIOSE T; YAMANAKA T; NEMOTO M; KONDO T; MATSUMURA T
    J Vet Med Sci; 2009 Nov; 71(11):1439-48. PubMed ID: 19959893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity.
    Guo PX; Goebel S; Perkus ME; Taylor J; Norton E; Allen G; Languet B; Desmettre P; Paoletti E
    J Virol; 1990 May; 64(5):2399-406. PubMed ID: 2157895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Solid matrix-antibody-antigen complexes incorporating equine herpesvirus 1 glycoproteins C and D elicit anti-viral immune responses in BALB/c (H-2K(d)) and C3H (H-2K(k)) mice.
    Alber DG; Killington RA; Stokes A
    Vaccine; 2000 Nov; 19(7-8):895-901. PubMed ID: 11115713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro and in vivo characterization of equine herpesvirus type 1 (EHV-1) mutants devoid of the viral chemokine-binding glycoprotein G (gG).
    von Einem J; Smith PM; Van de Walle GR; O'Callaghan DJ; Osterrieder N
    Virology; 2007 May; 362(1):151-62. PubMed ID: 17250864
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of a type-specific enzyme-linked immunosorbent assay for equine herpesvirus types 1 and 4 (EHV-1 and -4) to horse populations inoculated with inactivated EHV-1 vaccine.
    Yasunaga S; Maeda K; Matsumura T; Kondo T; Kai K
    J Vet Med Sci; 2000 Jul; 62(7):687-91. PubMed ID: 10945284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
    Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
    J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell-mediated antiviral response to equine herpesvirus type 1 demonstrated in a murine infection model by means of adoptive transfer of immune cells.
    Azmi M; Field HJ
    J Gen Virol; 1993 Feb; 74 ( Pt 2)():275-80. PubMed ID: 8381468
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D.
    Meseda CA; Stout RR; Weir JP
    Viral Immunol; 2006; 19(2):250-9. PubMed ID: 16817767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Equine herpesvirus-1 strain KyA, a candidate vaccine strain, reduces viral titers in mice challenged with a pathogenic strain, RacL.
    Colle CF; Tarbet EB; Grafton WD; Jennings SR; O'Callaghan DJ
    Virus Res; 1996 Aug; 43(2):111-24. PubMed ID: 8864201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice.
    Li Y; Ye J; Cao S; Xiao S; Zhao Q; Liu X; Jin M; Chen H
    J Gene Med; 2009 Jan; 11(1):57-65. PubMed ID: 19006097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitation of virus-specific classes of antibodies following immunization of mice with attenuated equine herpesvirus 1 and viral glycoprotein D.
    Zhang Y; Smith PM; Jennings SR; O'Callaghan DJ
    Virology; 2000 Mar; 268(2):482-92. PubMed ID: 10704356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant herpesvirus glycoprotein G improves the protective immune response to Helicobacter pylori vaccination in a mouse model of disease.
    Baker L; Chitas AM; Hartley CA; Coppo MJ; Vaz PK; Stent A; Gilkerson JR; Devlin JM; Every AL
    PLoS One; 2014; 9(5):e96563. PubMed ID: 24794215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The characterization of neutralizing and non-neutralizing monoclonal antibodies against equid herpesvirus type 1.
    Sinclair R; Cook RF; Mumford JA
    J Gen Virol; 1989 Feb; 70 ( Pt 2)():455-9. PubMed ID: 2543748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of different prime-boost regimes with DNA and recombinant Orf virus based vaccines expressing glycoprotein D of pseudorabies virus in pigs.
    van Rooij EM; Rijsewijk FA; Moonen-Leusen HW; Bianchi AT; Rziha HJ
    Vaccine; 2010 Feb; 28(7):1808-13. PubMed ID: 20018271
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules.
    Eo SK; Gierynska M; Kamar AA; Rouse BT
    J Immunol; 2001 May; 166(9):5473-9. PubMed ID: 11313385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of membrane-bound and secreted forms of equine herpesvirus 1 glycoprotein D by recombinant baculovirus.
    Flowers CC; Flowers SP; Sheng Y; Tarbet EB; Jennings SR; O'Callaghan DJ
    Virus Res; 1995 Jan; 35(1):17-34. PubMed ID: 7754672
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serological responses and clinical outcome after vaccination of mares and foals with equine herpesvirus type 1 and 4 (EHV-1 and EHV-4) vaccines.
    Bresgen C; Lämmer M; Wagner B; Osterrieder N; Damiani AM
    Vet Microbiol; 2012 Nov; 160(1-2):9-16. PubMed ID: 22633483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.